Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery.
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
04
2019
revised:
16
07
2019
accepted:
01
08
2019
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
24
3
2020
Statut:
epublish
Résumé
Pancreatic tumors and their surgical resection are associated with significant morbidity and mortality, and the biomarkers currently used for these conditions have limited sensitivity and specificity. Because calprotectin and calgranulin C serum levels have been demonstrated to be potential biomarkers of certain cancers and complications of major surgery, the levels of both proteins were tested in the current study in patients with benign and malignant pancreatic tumors that were surgically removed. The baseline serum levels and kinetics of calprotectin and calgranulin C during the 7-day postoperative period were evaluated with immunoassays in 98 adult patients who underwent pancreatic surgery. The baseline serum levels of calprotectin and calgranulin C in patients with malignant (
Identifiants
pubmed: 31582902
doi: 10.1155/2019/6985703
pmc: PMC6754944
doi:
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
S100A12 Protein
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6985703Informations de copyright
Copyright © 2019 Michal Holub et al.
Déclaration de conflit d'intérêts
None of the authors have declared direct financial relations with the trademarks mentioned in the paper that might lead to a conflict of interest.
Références
Clin Rheumatol. 2018 Aug;37(8):2055-2062
pubmed: 29656372
Pancreas. 2014 Jan;43(1):22-7
pubmed: 24326364
Shock. 2015 Feb;43(2):109-16
pubmed: 25394242
J Clin Invest. 2012 Aug;122(8):2711-9
pubmed: 22850880
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
J Invest Surg. 2017 Jun;30(3):152-161
pubmed: 27689623
Mol Med Rep. 2015 Jun;11(6):4093-100
pubmed: 25673070
BMC Cancer. 2018 Dec 17;18(1):1255
pubmed: 30558665
Clin Biochem. 2014 Aug;47(12):1065-8
pubmed: 24440500
PLoS One. 2013 Jul 18;8(7):e68694
pubmed: 23874727
Arch Surg. 2003 Dec;138(12):1310-4; discussion 1315
pubmed: 14662530
Surgery. 2014 Sep;156(3):591-600
pubmed: 25061003
Int J Inflam. 2012;2012:907078
pubmed: 22811950
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Clin Chim Acta. 2016 May 1;456:24-30
pubmed: 26923392
Int J Mol Med. 2014 Apr;33(4):769-76
pubmed: 24481067
Crit Care Resusc. 2017 Sep;19(3):205-213
pubmed: 28866970
Surgery. 2014 Jun;155(6):977-88
pubmed: 24856119
APMIS. 2018 Feb;126(2):152-159
pubmed: 29700911
Arthritis Rheum. 2004 Apr;50(4):1286-95
pubmed: 15077313
Scand J Trauma Resusc Emerg Med. 2017 Nov 25;25(1):114
pubmed: 29178941
Scand J Clin Lab Invest. 2005;65(3):211-20
pubmed: 16095050
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Ann Surg Oncol. 2011 Aug;18(8):2126-35
pubmed: 21336514
Shock. 2013 Sep;40(3):188-94
pubmed: 23846410
Eur Arch Otorhinolaryngol. 2017 Jun;274(6):2499-2504
pubmed: 28251322
J Am Coll Surg. 2012 Jan;214(1):46-52
pubmed: 22192922
Medicine (Baltimore). 2016 Apr;95(17):e3510
pubmed: 27124059
HPB (Oxford). 2017 Jul;19(7):580-586
pubmed: 28392159
HPB (Oxford). 2014 Jan;16(1):20-33
pubmed: 23464850
Cytokine. 2017 Apr;92:80-82
pubmed: 28110121
Diagn Microbiol Infect Dis. 2019 Mar;93(3):219-226
pubmed: 30420210
J Rheumatol. 2010 Nov;37(11):2369-76
pubmed: 20810496